---
title: "Zai Lab Ltd. to Announce Fourth Quarter and Full Year Financial Results"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275466803.md"
datetime: "2026-02-10T13:30:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275466803.md)
  - [en](https://longbridge.com/en/news/275466803.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275466803.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275466803.md) | [English](https://longbridge.com/en/news/275466803.md)


# Zai Lab Ltd. to Announce Fourth Quarter and Full Year Financial Results

Zai Lab Ltd. will announce its fourth quarter and full year 2025 financial results and provide recent corporate updates on February 26, 2026, before the opening of U.S. equity markets. Results will be released on the Company’s website at here. A conference call and webcast will be held on February 26, 2026, at 8:00 a.m. ET (9:00 p.m. HKT). Participants can register for the webcast via the following link: Registration link for webcast (preferred) (here) or for the dial-in via Registration link for dial-in (here). Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260210221858) on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相關股票

- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [iShares US Medical Devices (IHI.US)](https://longbridge.com/zh-HK/quote/IHI.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [Zai Lab (ZLAB.US)](https://longbridge.com/zh-HK/quote/ZLAB.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [SPDR S&P Health Equip (XHE.US)](https://longbridge.com/zh-HK/quote/XHE.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)

## 相關資訊與研究

- [Prelude Therapeutics reports $99.5 mln net loss for 2025](https://longbridge.com/zh-HK/news/278542482.md)
- [Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend](https://longbridge.com/zh-HK/news/279032442.md)
- [Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027](https://longbridge.com/zh-HK/news/278775473.md)
- [Oragenics receives HREC approval, begins Phase IIa ONP-002 site initiation in Australia](https://longbridge.com/zh-HK/news/278776483.md)
- [bioAffinity Launches Major Lung Cancer Detection Study](https://longbridge.com/zh-HK/news/278565253.md)